Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$3.10B
EBITDA Margin
-359.19%
TTM Avg
-174.35%
3Y Avg
-417.41%
5Y Avg
-1450.57%
Market Cap
$3.09B
EBITDA Margin
-1.82%
TTM Avg
-32.91%
3Y Avg
-2154.05%
5Y Avg
-2154.05%
Market Cap
$3.12B
EBITDA Margin
-54.45%
TTM Avg
-179.51%
3Y Avg
-231.98%
5Y Avg
-287.87%
Market Cap
$2.89B
EBITDA Margin
89.92%
TTM Avg
49.57%
3Y Avg
44.47%
5Y Avg
4968.54%
Market Cap
$2.82B
EBITDA Margin
22.42%
TTM Avg
17.70%
3Y Avg
-0.76%
5Y Avg
-37.34%
Market Cap
$3.40B
EBITDA Margin
-21676.57%
TTM Avg
-21676.57%
3Y Avg
-14888.43%
5Y Avg
-11379.97%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | $3.09B | N/A | N/A | N/A | N/A |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.10B | -359.19% | -174.35% | -417.41% | -1450.57% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.09B | -1.82% | -32.91% | -2154.05% | -2154.05% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.12B | -54.45% | -179.51% | -231.98% | -287.87% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.89B | 89.92% | 49.57% | 44.47% | 4968.54% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.39B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.82B | 22.42% | 17.70% | -0.76% | -37.34% |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.40B | -21676.57% | -21676.57% | -14888.43% | -11379.97% |
| AtriCure, Inc. (ATRC)vs › | $2.78B | 3.20% | -0.69% | -3.43% | -1.09% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.44B | 10.88% | 18.32% | -3.89% | -19.05% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
